TOP TEN perturbations for 39471_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39471_at
Selected probe(set): 200723_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39471_at (200723_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.692504Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-2.4398603Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.2315989Number of Samples:5 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM1) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):2.164568Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-18) |
| Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):1.8590717Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
endometriosis study 6 (minimal/mild endo.; mid-se MCP) / normal endometrium tissue (mid-se MCP)
Relative Expression (log2-ratio):-1.80721Number of Samples:9 / 8
| Experimental | endometriosis study 6 (minimal/mild endo.; mid-se MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the mid-secretory menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (mid-se MCP) |
| Normal endometrial tissue samples from women collected in the mid-secretory menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.7578392Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.694397Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):1.6893578Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.686595Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |